Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer [1] [2] [3].
In Vivo, Anti-Mouse/Human CD11b Antibody (M1/70) (2.5 mg/kg, i.p., once every 2 days, for 14 days) significantly reduces renal fibrosis and inflammation in male C57BL/6J mice with an ischemiareperfusion injury (IRI) model[1]. Anti-Mouse/Human CD11b Antibody (M1/70) (50 μg, i.v., single dose) significantly inhibits the adhesion of DCs to damaged blood vessels in wild type C57BL/6 mice with a carotid artery ligation model[2]. Anti-Mouse/Human CD11b Antibody (M1/70) (60 μg, intratumoral injection, once daily, for 5 days) significantly inhibits tumor growth in female anthymic Nude-Foxn1nu mice bearing SKOV-3 tumors[3].
In Vitro, Anti-Mouse/Human CD11b Antibody (M1/70) (10 μg/mL, 30 min) significantly inhibits the adhesion of bone marrow-derived dendritic cells (bmDCs) to fixed platelets[2]. Anti-Mouse/Human CD11b Antibody (M1/70) (5-10 μg/mL, 24 h) significantly kills epithelial ovarian cancer (EOC) cells[3]. Anti-Mouse/Human CD11b Antibody (M1/70) (5-15 μg/mL, 36 h) dose dependently inhibits cell migration in SKOV-3 and MDAH-2774 cells[3].
References:
[1]. Zhou H, et al. CD11b deficiency attenuates the ischemia/reperfusion-induced AKI-to-CKD process by regulating macrophage polarization. FASEB J. 2024 Dec 15;38(23):e70216.
[2]. Nording H, et al. Activated Platelets Upregulate β2 Integrin Mac-1 (CD11b/CD18) on Dendritic Cells, Which Mediates Heterotypic Cell-Cell Interaction. J Immunol. 2022 Apr 1;208(7):1729-1741.
[3]. Saed GM, et al. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target. Gynecol Oncol. 2018 Mar;148(3):567-575.
In Vivo, Anti-Mouse/Human CD11b Antibody (M1/70) (2.5 mg/kg, i.p., once every 2 days, for 14 days) significantly reduces renal fibrosis and inflammation in male C57BL/6J mice with an ischemiareperfusion injury (IRI) model[1]. Anti-Mouse/Human CD11b Antibody (M1/70) (50 μg, i.v., single dose) significantly inhibits the adhesion of DCs to damaged blood vessels in wild type C57BL/6 mice with a carotid artery ligation model[2]. Anti-Mouse/Human CD11b Antibody (M1/70) (60 μg, intratumoral injection, once daily, for 5 days) significantly inhibits tumor growth in female anthymic Nude-Foxn1nu mice bearing SKOV-3 tumors[3].
In Vitro, Anti-Mouse/Human CD11b Antibody (M1/70) (10 μg/mL, 30 min) significantly inhibits the adhesion of bone marrow-derived dendritic cells (bmDCs) to fixed platelets[2]. Anti-Mouse/Human CD11b Antibody (M1/70) (5-10 μg/mL, 24 h) significantly kills epithelial ovarian cancer (EOC) cells[3]. Anti-Mouse/Human CD11b Antibody (M1/70) (5-15 μg/mL, 36 h) dose dependently inhibits cell migration in SKOV-3 and MDAH-2774 cells[3].
References:
[1]. Zhou H, et al. CD11b deficiency attenuates the ischemia/reperfusion-induced AKI-to-CKD process by regulating macrophage polarization. FASEB J. 2024 Dec 15;38(23):e70216.
[2]. Nording H, et al. Activated Platelets Upregulate β2 Integrin Mac-1 (CD11b/CD18) on Dendritic Cells, Which Mediates Heterotypic Cell-Cell Interaction. J Immunol. 2022 Apr 1;208(7):1729-1741.
[3]. Saed GM, et al. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target. Gynecol Oncol. 2018 Mar;148(3):567-575.